EMA Authorised: Matever (levetiracetam) — Pharmathen S.A.

View source ↗

Summary

The EMA authorised Matever (levetiracetam) by Pharmathen S.A. for the treatment of epilepsy. Decision date: 16 December 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Matever (levetiracetam)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Pharmathen S.A.. Decision date: 16/12/2025